Safety and effectiveness of eculizumab in Japanese patients withgeneralized myasthenia gravis: interim analysis of post-marketingsurveillance

摘要

Eculizumab, a humanized monoclonal antibody targeted to terminal complementprotein C5, is approved in Japan for treatment of patients withanti-acetylcholine receptor antibody-positive (AChR+) generalized myastheniagravis (gMG) whose symptoms are difficult to control with high-doseintravenous immunoglobulin (IVIg) therapy or plasmapheresis.